TABLE 4.
Characteristics and management of five patients with pre‐MDS hematological disorders
| Hematological abnormalities | PARPi (no cycles) | Karyotype analysis | Mutations (VAF) a | Diagnosis | Morphology (WHO criteria) | PARPi management | |
|---|---|---|---|---|---|---|---|
| ID1 | Erythroblastosis with H‐Jolly bodies | Olaparib (14) | 46,XX[8]/46,XX, inv(17)(q21q25) | TP53 (6.10%) | CCAUS | Normal | Stop |
| ID2 | N G3 and T G2 | Olaparib (26) | 45,XX, del(5)(q22q35), −17[6]/46,XX[15] | TP53 (12%) | CCUS | Normal | Stop |
| ID3 | A G3 and T G2 | Niraparib (4) | nd b | Negative | ICUS (transient) | Normal | Continued |
| ID4 | N G2 | Olaparib (6) | nd b | Negative | ICUS (transient) | Normal | Continued |
| ID5 | A G2 | Olaparib (13) | nd b | Negative | ICUS (transient) | Normal | Continued |
Abbreviations: A, anemia; CCAUS, clonal cytogenetic abnormalities of undetermined significance; CCUS, clonal cytopenia of undetermined significance; G, grade according to Common Terminology Criteria for Adverse Events; ICUS, idiopathic cytopenia of undetermined significance; N, neutropenia; PARPi, poly(ADP‐ribose) polymerase inhibitors; T, thrombocytopenia; transient, recovery after PARPi interruption and recurring after PARPi resumption; VAF, variant allele frequency.
Next generation sequencing analysis of PB DNA using Oncomine Myeloid Research Assay and the Ion Torrent S5 technology (ThermoFisher).
Nd, not done, due to only transient blood counts abnormalities and no detectable mutations by NGS.